Palisade Bio, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical issuer developing oral PDE4 inhibitor prodrugs. Disclosures include proxy materials for annual and special stockholder meetings, director elections, auditor ratification, charter-amendment voting matters and compensation-plan governance.
Material-event reports and registration statements cover clinical-development service arrangements, common-stock sales, securities registration, capital-structure updates, Nasdaq listing compliance and meeting adjournment or withdrawal actions. The filings also provide formal context for PALI-2108 development activities, equity financing mechanics, corporate governance and public-company reporting obligations.
Palisade Bio, Inc. (PALI) General Counsel & Corporate Secretary Julien E. Capers reported an award of 787,300 restricted stock units on October 19, 2026. Each RSU represents a contingent right to receive one common share, and the reported post-transaction position was 787,300 shares. The award is subject to service-based vesting.
Palisade Bio, Inc. reported that President & Chief Medical Officer Mitchell Lawrence Jones received 2,620,850 common shares on October 6, 2026, upon settlement of vested restricted stock units. The issuer withheld 1,031,102 shares to satisfy his income tax withholding and remittance obligations. The RSU vesting schedules were subject to continuous service through each vesting date.
Palisade Bio, Inc. (PALI) reported that CEO and CFO John David Finley received 3,227,384 common shares on October 6, 2026, upon settlement of vested restricted stock units. The reported derivative transactions involved 3,059,800 and 167,584 RSUs. The company withheld 1,411,982 shares for Finley’s income-tax withholding and remittance obligations; the footnote states no shares would be sold in the public market for that purpose. Separately, 88,451 shares were held indirectly through FCW Investments, LLC, where Finley has sole investment and voting power.
Palisade Bio, Inc. (PALI) director Donald Allen Williams reported two direct purchases of common stock: 10,000 shares at $1.4200 per share on October 1, 2026, and 10,000 shares at $1.4600 per share on October 2, 2026. No Rule 10b5-1 plan is reported. Separately, 3,000 shares were held indirectly through the reporting person's defined benefit plan as of October 1, 2026.
PALISADE BIO, INC. (PALI) reported that its CEO and CFO, John David Finley, made an internal reallocation of holdings through bona fide gifts of common stock on August 19, 2026. He transferred 88,400 shares of common stock from his direct ownership to FCW Investments, LLC, an entity he manages.
After these related gift transactions, Finley directly holds 129,288 shares of Palisade Bio common stock and indirectly holds 88,451 shares through FCW Investments, LLC, over which he has sole investment and voting power. The Rule 10b5-1 trading plan checkbox was not marked for these transactions.
Palisade Bio, Inc. is reported by Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz as a group holding no beneficial ownership of its common stock. Each filer reports 0.00 shares with 0.0% of the class and no sole or shared voting or dispositive power. The group also confirms ownership of 5 percent or less of Palisade Bio’s common stock.
Palisade Bio, Inc. received an amended Schedule 13G reporting that Soleus Capital Master Fund, L.P. and related Soleus entities collectively report beneficial ownership of 13,063,687 shares of Palisade Bio common stock. Based on 174,270,558 shares outstanding as of August 6, 2026, this represents 7.5% of the company’s common stock.
The filing lists zero sole voting and dispositive power and 13,063,687 shares of shared voting and shared dispositive power for each reporting person. The shares are held directly by Soleus Capital Master Fund, L.P., with several affiliated Soleus entities and Guy Levy reported as having shared power through their roles, while each disclaims beneficial ownership beyond Section 13(d) reporting purposes.
Palisade Bio reported second quarter 2026 results and progress on its lead IBD candidate PALI-2108. The company highlighted favorable Phase 1 safety, exposure and pharmacodynamic data, with all 5 ulcerative colitis patients showing clinical response and 2 achieving remission, and a roughly 47.5% mean SES-CD reduction in fibrostenotic Crohn’s disease patients.
PALI-2108 is advancing into Phase 2 trials: the ASCENTRA-UC study is expected to start in the second half of 2026 with primary efficacy results in the second half of 2027, and an IND for the ASCENTRA-CD Phase 2 trial is planned for the second half of 2026, with primary readout in early 2028. For the quarter ended June 30, 2026, Palisade reported $0.5 million in license revenue, research and development expenses of $7.4 million, general and administrative expenses of $4.8 million and a net loss of $10.6 million or $0.05 per share. Cash and cash equivalents were $125.2 million as of June 30, 2026, which the company believes will fund operations through the planned Phase 2 efficacy readouts.
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company developing PALI-2108 for inflammatory bowel disease, advancing from Phase 1 into global Phase 2 programs (ASCENTRA-UC and planned ASCENTRA-CD). In June 2026, the FDA cleared an IND for the ASCENTRA-UC Phase 2 trial, with first patient enrollment expected in the second half of 2026.
For the three months ended June 30, 2026, the company reported $0.5 million of license revenue, all from a milestone under the Newsoara co-development agreement. Research and development expenses rose to $7.4 million and general and administrative expenses to $4.8 million, driven largely by higher headcount, program spending on PALI-2108, and significantly higher stock-based compensation. Net loss for the quarter was $10.6 million, and $20.2 million for the first six months of 2026.
Cash, cash equivalents and restricted cash totaled $125.2 million at June 30, 2026, down modestly from $133.4 million at year-end 2025. Management states this balance is sufficient to fund operations through key Phase 2 efficacy readouts in UC and CD into early 2028. The company continues to disclose a longstanding material weakness in internal control over financial reporting related to segregation of duties and formalized close processes, though it believes its financial statements are fairly presented.